RIGL vs UBER · P/E 9.1, rev $179.3M vs P/E 18, rev $52.02B
Rigel Pharmaceuticals Inc (RIGL) versus Uber Technologies Inc (UBER) — a side-by-side from cached financials, not a winner call.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
Uber Technologies Inc (UBER) is a software - application company listed on NYSE. It is led by Dara Khosrowshahi.
Latest reported RIGL revenue for 2024-12-31 was $179.3M. Net income was $17.5M. Revenue was up 53.4% from 2023-12-31 to 2024-12-31. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Latest reported UBER revenue for 2025-12-31 was $52.02B. Net income was $10.05B. Revenue was up 18.3% from 2024-12-31 to 2025-12-31. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
RIGL currently screens at market cap $338.3M and trailing P/E 9.1. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
Not investment advice. Open the RIGL and UBER stock pages for the full models.
Not investment advice.